MRNA Quote, Financials, Valuation and Earnings

Biogen has a net margin of -907.48% compared to Moderna's net margin of 9.89%. Moderna's return on equity of -29.23% beat Biogen's return on equity of 9.11%.

Moderna has a consensus price target of $46.96, signalling upside risk potential of 93.66%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 45.76%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Moderna has a beta of 1.995, which suggesting that the stock is 99.542% more volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Biogen quarterly revenues of $2.4B. Moderna's net income of -$971M is lower than Biogen's net income of $240.5M. Notably, Moderna's price-to-earnings ratio is -- while Biogen's PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.01x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -907.48% compared to Moderna's net margin of 24.92%. Moderna's return on equity of -29.23% beat Biomarin Pharmaceutical's return on equity of 9.62%.

Moderna has a consensus price target of $46.96, signalling upside risk potential of 93.66%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.02 which suggests that it could grow by 63.13%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Moderna has a beta of 1.995, which suggesting that the stock is 99.542% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Moderna's net income of -$971M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Moderna's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.01x versus 3.94x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -907.48% compared to Moderna's net margin of -60.08%. Moderna's return on equity of -29.23% beat Sarepta Therapeutics's return on equity of -20.94%.

Moderna has a consensus price target of $46.96, signalling upside risk potential of 93.66%. On the other hand Sarepta Therapeutics has an analysts' consensus of $96.72 which suggests that it could grow by 166.66%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Moderna has a beta of 1.995, which suggesting that the stock is 99.542% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Moderna's net income of -$971M is lower than Sarepta Therapeutics's net income of -$447.5M. Notably, Moderna's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.01x versus 1.80x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -907.48% compared to Moderna's net margin of 23.33%. Moderna's return on equity of -29.23% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Moderna has a consensus price target of $46.96, signalling upside risk potential of 93.66%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 17.72%. Given that Moderna has higher upside potential than Vertex Pharmaceuticals, analysts believe Moderna is more attractive than Vertex Pharmaceuticals.

Moderna has a beta of 1.995, which suggesting that the stock is 99.542% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Moderna's net income of -$971M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Moderna's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.01x versus 9.92x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.